News Novo Nordisk looks east for another obesity therapy Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.
News AstraZeneca buys cell therapy biotech for up to $1bn AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News Biogen bags rights to epilepsy drug from Stoke in $550m deal Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.
News When licensing deals go bad - Novo sues KBP Bio for $830m Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.